Today is National Grammar Day. Before anyone of our posts goes online, it dashes thorough a gauntlet of reviewers. Those reviewers collectively possess just the right amount of neurotic fastidiousness to ensure that what emerges is mostly correct and at least intermittently coherent. Some of us pretend to actually know Strunk & White by heart. Still, errors occasionally evade the dragnet of dorks. In honor of National Grammar Day, we have festooned today’s post with enough errors to keep all of you grammar cops busy. We do this as a matter of principal.
But there are no errors in the case under review. We have a rare favorable medical device decision out of the Seventh Circuit. The case is called Kallal v. Ciba Vision Corporation Inc., 2015 U.S. App. LEXIS 2987 (7th Cir. Feb. 24, 2015). Mind you, the Seventh Circuit is one court we think the world of. Any court that is home to legal luminaries like Posner, Easterbrook, Wood, et al. must be fairy formidable. But the Seventh Circuit is also home to the hideous Bausch precedent. Perhaps you remember Bausch. Its hard to forget. The Seventh Circuit permitted a plaintiff to vaguely state a parallel claim which lacked substance under both federal and state law. TwIqbal pleading requirements impacted the case not at all. Irregardless of the Supreme Court’s instruction that lame cases should be dismissed before subjecting defendants’ to expensive discovery, the Bausch court elevated the plaintiff’s desire for discovery into something sacramental.
But Kallal is much better than that is. The plaintiff claimed that defective contact lenses had hurt his eyes. The plaintiff did not have alot of evidence. The company had recalled some of it’s contact lenses. Courageously (after Bausch) the district court held that the plaintiff’s claims were preempted nonetheless, and that the parallel claim could not save the case. The plaintiff argued that his suite fit inside of the Riegel exception because the company failed to list ion permeability as a “material characteristic” in its premarket approval list. The company responded that the FDA did not require them to meet any ion permeability threshold. The plaintiff did not offer any evidence to the contrary. In any jurisdiction but Bausch-land, that argument would win the preemption day for the defendant. And mirabile dictum, it managed to win for the defendant in Kallal. At least at the lower court’s level.Continue Reading An Error-free Seventh Circuit Medical Device Case